- Home
- COCH vs GDTC Comparison
COCH vs GDTC Comparison
Compare COCH & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCH
- GDTC
- Stock Information
- Founded
- COCH 1995
- GDTC 2018
- Country
- COCH United States
- GDTC Singapore
- Employees
- COCH N/A
- GDTC N/A
- Industry
- COCH Blank Checks
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- COCH Finance
- GDTC Health Care
- Exchange
- COCH Nasdaq
- GDTC Nasdaq
- Market Cap
- COCH 31.6M
- GDTC 28.0M
- IPO Year
- COCH N/A
- GDTC 2023
- Fundamental
- Price
- COCH $1.53
- GDTC $2.05
- Analyst Decision
- COCH Strong Buy
- GDTC Buy
- Analyst Count
- COCH 2
- GDTC 1
- Target Price
- COCH $9.25
- GDTC $5.00
- AVG Volume (30 Days)
- COCH 30.5K
- GDTC 9.2K
- Earning Date
- COCH 05-01-2025
- GDTC 01-01-0001
- Dividend Yield
- COCH N/A
- GDTC N/A
- EPS Growth
- COCH N/A
- GDTC N/A
- EPS
- COCH N/A
- GDTC N/A
- Revenue
- COCH $212,000.00
- GDTC $368,838.00
- Revenue This Year
- COCH $8.04
- GDTC $5.37
- Revenue Next Year
- COCH $15.39
- GDTC N/A
- P/E Ratio
- COCH N/A
- GDTC N/A
- Revenue Growth
- COCH N/A
- GDTC N/A
- 52 Week Low
- COCH $1.21
- GDTC $1.20
- 52 Week High
- COCH $3.99
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- COCH 49.57
- GDTC 40.07
- Support Level
- COCH $1.39
- GDTC $2.00
- Resistance Level
- COCH $1.70
- GDTC $2.45
- Average True Range (ATR)
- COCH 0.13
- GDTC 0.12
- MACD
- COCH -0.03
- GDTC -0.02
- Stochastic Oscillator
- COCH 33.92
- GDTC 11.16
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.